{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:57:10Z","timestamp":1793721430349,"version":"4.6.1"},"reference-count":157,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Drug and Alcohol Abuse"],"published-print":{"date-parts":[[2016,3,3]]},"DOI":"10.3109\/00952990.2015.1109648","type":"journal-article","created":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T03:18:27Z","timestamp":1453778307000},"page":"117-128","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Legal regimes surrounding naloxone access: considerations for prescribers"],"prefix":"10.3109","volume":"42","author":[{"given":"Joy E.","family":"Brodrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin K.","family":"Brodrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryon","family":"Adinoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,1,25]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2008.136937"},{"key":"CIT0002","volume-title":"Opioid Painkiller Prescribing. Centers for Disease Control and Prevention website","author":"National Center for Injury Prevention and Control"},{"key":"CIT0003","volume-title":"Overdose Death Rates. National Institute on Drug Abuse website","author":"National Institute on Drug Abuse"},{"key":"CIT0004","first-page":"849","volume":"63","author":"RA Rudd","year":"2014","journal-title":"MMWR"},{"key":"CIT0005","volume-title":"Department of Health and Human Services. Addressing Prescription Drug Abuse in the United States Current Activities and Future Opportunities","author":"Behavioral Health Coordinating Committee, Prescription Drug Abuse Subcommittee, U.S"},{"key":"CIT0006","volume-title":"Heroin gains popularity as cheap doses flood the U.S","author":"Gray E."},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.366"},{"key":"CIT0008","first-page":"273","volume":"1","author":"Burris S","year":"2009","journal-title":"Drexel Law Rev"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aen094"},{"key":"CIT0010","volume-title":"Lexi-Comp Online\u00ae, Lexi-Drugs\u00ae, Hudson, Ohio: Lexi-Comp, Inc","year":"2014"},{"key":"CIT0011","volume-title":"FDA approves new hand-held auto-injector to reverse opioid overdose","author":"U.S. Food and Drug Administration","year":"2014"},{"key":"CIT0012","volume-title":"Richmond, VA","author":"EVZIO\u2122 [package insert]","year":"2014"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1080\/10903120903144866"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2008.12.009"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2014.42584"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2014.302062"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1111\/acem.12485"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2006.05.025"},{"key":"CIT0019","first-page":"631","volume":"64","author":"Centers for Disease Control and Prevention. Opioid overdose prevention programs providing naloxone to laypersons \u2013 United States","year":"2015","journal-title":"MMWR"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000034"},{"key":"CIT0021","volume-title":"Overdose Rescue & Naloxone: Long-format training","author":"DOPE Project\/San Francisco Department of Public Health"},{"key":"CIT0022","volume-title":"Naloxone Program Case Studies. Harm Reduction Coalition website","author":"Harm Reduction Coalition"},{"key":"CIT0023","volume-title":"Overdose Prevention & Naloxone Enrollment Form","author":"Vermont Department of Health"},{"key":"CIT0024","volume-title":"Intranasal Naloxone Kit Discharge Order Protocol. Prescribe to Prevent website","author":"Center Boston Medical"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-14-297"},{"issue":"174","key":"CIT0026","volume":"346","author":"Walley AY","year":"2013","journal-title":"BMJ"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1093\/jurban\/jti053"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2009.01.003"},{"key":"CIT0029","volume-title":"Lists of: Scheduling Actions Controlled Substances Regulated Chemicals","author":"U.S. Department of Justice Drug Enforcement Administration"},{"key":"CIT0030","volume-title":"Naloxone \u2013 sold to and administered by qualified first responders","year":"2014"},{"key":"CIT0032","volume-title":"Good Samaritan and Naloxone Bill Status Report \u2013 Carryover 2015 and Special Sessions","author":"National Alliance for Model State Drug Laws"},{"key":"CIT0033","volume-title":"Opioid antagonist \u2013 prescriptions authorized; administration; liability, Ala","year":"1975"},{"key":"CIT0034","volume-title":"Drugs and medicine \u2013 physicians and dentists \u2013 opioid antagonist \u2013 drug overdoses, H.B. 208","year":"2015"},{"key":"CIT0035","volume-title":"Administration of opiate antagonists; training; immunity; designation by director","year":"2015"},{"key":"CIT0036","volume-title":"Opioid antagonist \u2013 Immunity","year":"2015"},{"key":"CIT0037","volume-title":"Furnishing of naloxone hydrochloride; development of standardized procedures or protocols, Cal","year":"2015"},{"key":"CIT0038","volume-title":"Protocol for Pharmacists Furnishing Naloxone Hydrochloride, 16 CCR \u00a7 1746.3","year":"2015"},{"key":"CIT0039","volume-title":"Unprofessional conduct, C.R.S.A. \u00a7 12-36-117","year":"2015"},{"key":"CIT0040","volume-title":"Grounds for discipline, C.R.S.A. \u00a7 12-38-117","year":"2015"},{"key":"CIT0041","volume-title":"Prescribing opiate antagonists \u2013 definitions, C.R.S.A. \u00a7 12-38-125.5","year":"2015"},{"key":"CIT0042","doi-asserted-by":"crossref","unstructured":"Rules, C.R.S.A. \u00a7 12-42.5-105 (2015).","DOI":"10.1365\/s35147-015-1312-6"},{"key":"CIT0043","volume-title":"Prescription required \u2013 exception \u2013 dispensing opiate antagonists \u2013 definitions, C.R.S.A. \u00a7 12-42.5-120","year":"2015"},{"key":"CIT0044","volume-title":"Unprofessional conduct \u2013 grounds for discipline, C.R.S.A. \u00a7 12-42.5-123","year":"2015"},{"key":"CIT0045","volume-title":"Persons rendering emergency assistance through the administration of an opiate antagonist \u2013 limited immunity \u2013 legislative declaration \u2013 definitions, C.R.S.A. \u00a7 13-21-108.7","year":"2015"},{"key":"CIT0046","volume-title":"Immunity for a person who administers an opiate antagonist during an opiate-related drug overdose event \u2013 definitions","year":"2015"},{"key":"CIT0047","volume-title":"Immunity for prescribing, dispensing or administering an opioid antagonist to treat or prevent a drug overdose, C.G.S.A. \u00a7 17a-714a","year":"2015"},{"key":"CIT0048","volume-title":"Community-based Naloxone access program, 16 Del.C. \u00a7 138","year":"2014"},{"key":"CIT0049","volume-title":"Administration of naloxone by peace officers and the Community-Based Naloxone Access Program, 16 Del.C. \u00a7 3001G","year":"2014"},{"key":"CIT0050","unstructured":"Seeking health care for an overdose victim, D.C. Code \u00a7 7\u2013403 (2013)."},{"key":"CIT0051","volume-title":"Emergency treatment for suspected opioid overdose, Fla. Stat. \u00a7 381.887","year":"2015"},{"key":"CIT0052","volume-title":"Opioid antagonists, Ga. Code \u00a7 26-4-116.2","year":"2014"},{"key":"CIT0053","volume-title":"Opioid antagonists; administration; issuance; liability, Ga. Code \u00a7 31-11-55.1","year":"2014"},{"key":"CIT0054","doi-asserted-by":"crossref","unstructured":"Practice of pharmacy, I.C. \u00a7 54\u20131704 (2015).","DOI":"10.1002\/anie.201408271"},{"key":"CIT0055","unstructured":"Violations and penalties, I.C. \u00a7 54\u20131732 (2015)."},{"key":"CIT0056","volume-title":"Opioid antagonists","year":"2015"},{"key":"CIT0057","unstructured":"Possession of legend drugs, I.C. \u00a7 54\u20131734 (2015)."},{"key":"CIT0058","volume-title":"Drug Overdose Prevention Program, 20 ILCS 301\/5-23","year":"2010"},{"key":"CIT0059","volume-title":"\u201cPrescriber\u201d defined","year":"2015"},{"key":"CIT0060","volume-title":"Prescribing or dispensing an overdose intervention drug without examination; conditions, IC \u00a7 16-42-27-2","year":"2015"},{"key":"CIT0061","volume-title":"Immunity from civil liability, IC \u00a7 16-42-27-3","year":"2015"},{"key":"CIT0062","volume-title":"Overdose intervention drug, IC \u00a7 16-18-2-263.9","year":"2015"},{"key":"CIT0063","volume-title":"Provider prescribing or dispensing naloxone; administration by third party; use of naloxone by person or agency authorized to administer medication; immunity from liability; administrative regulations; use of naloxone by schools, KRS \u00a7 217.186","year":"2015"},{"key":"CIT0064","volume-title":"Naloxone; first responder; prescription; administration to third party; limitation of liability, LA R.S. 40:978.1","year":"2014"},{"key":"CIT0065","volume-title":"Naloxone; prescription; dispensing; administration by third party; limitation of liability, LA R.S. 40:978.2","year":"2015"},{"key":"CIT0066","volume-title":"Naloxone hydrochloride","year":"2014"},{"key":"CIT0067","volume-title":"Overdose Response Program, MD Health Gen T. 13, Subt. 31","year":"2015"},{"key":"CIT0068","volume-title":"Prescription; restrictions on issuance, M.G.L.A","year":"2012"},{"key":"CIT0069","volume-title":"Opioid antagonist, M.G.L.A. 94C \u00a719B","year":"2014"},{"key":"CIT0070","volume-title":"Immunity from prosecution under Secs","year":"2012"},{"key":"CIT0071","doi-asserted-by":"crossref","unstructured":"Definitions, M.C.L.A. \u00a7 28.541 (2015).","DOI":"10.1080\/08998280.2015.11929336"},{"key":"CIT0072","volume-title":"Definitions; terms commencing \u201co\u201d and \u201cp\u201d, M.C.L.A. \u00a7 333.1106","year":"2014"},{"key":"CIT0073","volume-title":"Report on opioid-related fatalities, M.C.L.A. \u00a7 333.7421","year":"2014"},{"key":"CIT0074","volume-title":"Prescribing, dispensing, possessing, or administering opioid antagonist; powers and duties of prescriber, dispensing prescriber, and pharmacist; civil liability, M.C.L.A. \u00a7 333.17744b","year":"2014"},{"key":"CIT0075","volume-title":"Opioid antagonist; administration to individual suffering opioid-related overdose, M.C.L.A. \u00a7 691.1503","year":"2014"},{"key":"CIT0076","volume-title":"Legend drugs, who may prescribe, possess, M.S.A \u00a7 151.37","year":"2014"},{"key":"CIT0077","volume-title":"Good samaritan overdose prevention, M.S.A. ST \u00a7 604A.04","year":"2014"},{"key":"CIT0078","volume-title":"The Emergency Response and Overdose Prevention Act, H.B. 692","year":"2015"},{"key":"CIT0079","volume-title":"Naloxone, Neb.Rev.St. LB 390, \u00a7 11","year":"2015"},{"key":"CIT0080","volume-title":"Establishes an opioid overdose prevention policy for Nevada, S.B. 459","year":"2015"},{"key":"CIT0081","volume-title":"Persons and Corporations Exempted, N.H. Rev. Stat. \u00a7 318-B:15","year":"2015"},{"key":"CIT0082","volume-title":"Overdose Prevention, 24 NJ ST Subt. 1, Ch. 6J","year":"2013"},{"key":"CIT0083","volume-title":"Establishment of sterile syringe access program by municipalities, N.J.S.A. \u00a7 26:5C-28","year":"2015"},{"key":"CIT0084","volume-title":"Authority to administer opioid antagonists; release from liability, N.M.S.A. 1978, \u00a7 24-23-1","year":"2015"},{"key":"CIT0085","volume-title":"Health care professionals; release from liability, N.M.S.A. 1978, \u00a7 24-23-2","year":"2015"},{"key":"CIT0086","volume-title":"Authorization to administer opioid antagonists, N.M. Admin. Code","year":"2015"},{"key":"CIT0087","volume":"16","author":"Pharmacist N.M.","year":"2015","journal-title":"Code"},{"key":"CIT0088","volume-title":"Pharmacist prescriptive authority, N.M. Admin. Code","year":"2015"},{"key":"CIT0089","volume-title":"Opioid overdose prevention, NY Pub health \u00a7 3309","year":"2015"},{"key":"CIT0090","volume-title":"Opioid overdose prevention programs, 10 NYCRR 80.138","year":"2015"},{"key":"CIT0091","volume-title":"Treatment of overdose with opioid antagonist; immunity, N.C.G.S.A. \u00a7 90-106.2","year":"2015"},{"key":"CIT0092","volume-title":"A Bill for an Act to create and enact a new section to chapter 23-01 and a new subsection to section 43-15-11 of the North Dakota Century Code, relating to immunity from liability related to opioid antagonists and limited prescriptive authority for Naloxone rescue kits, S.B. 2104","year":"2015"},{"key":"CIT0093","volume-title":"Immunity for administration of naloxone, R.C. \u00a7 2925.61","year":"2015"},{"key":"CIT0094","volume-title":"Furnishing supply of, or issuing prescription for, naloxone without examining individual to whom it may be administered; immunity, R.C. \u00a7 4723.488","year":"2015"},{"key":"CIT0095","volume-title":"Priority of sale, distribution, and delivery of naloxone; immunity, R.C. \u00a7 4729.511","year":"2014"},{"key":"CIT0096","volume-title":"Furnishing supply of, or issuing prescription for, naloxone without examining individual to whom it may be administered; immunity, R.C. \u00a7 4730.431","year":"2015"},{"key":"CIT0097","volume-title":"Furnishing supply of, or issuing prescription for, naloxone without examining individual to whom it may be administered; immunity, R.C. \u00a7 4731.94","year":"2015"},{"key":"CIT0098","volume-title":"Administration of opiate antagonists, 63 Okl.St.Ann. \u00a7 1-2506.1","year":"2015"},{"key":"CIT0099","volume-title":"Prescription of opiate antagonists to family members, 63 Okl.St.Ann. \u00a7 1-2506.2","year":"2015"},{"key":"CIT0100","volume-title":"Sale or disposition of Naloxone, 63 Okl.St.Ann. \u00a7 2-312.2","year":"2015"},{"key":"CIT0101","volume-title":"Establishment of protocols and training on lifesaving treatments for opiate overdose; provision of training and supplies; immunity, O.R.S. \u00a7 689.681","year":"2015"},{"key":"CIT0102","volume-title":"Programs to treat allergic response or hypoglycemia, Oregon Administrative Code, Chapter 333, Division 55","year":"2015"},{"key":"CIT0103","volume-title":"Purpose, OAR 333-055-0100","year":"2015"},{"key":"CIT0104","volume-title":"Definitions, OAR 333-055-0105","year":"2015"},{"key":"CIT0105","volume-title":"Educational training, OAR 333-055-0110","year":"2015"},{"key":"CIT0106","volume-title":"Certificate of completion of training, OAR 333-055-0115","year":"2015"},{"key":"CIT0107","volume-title":"Definitions, OAR 855-041-2310","year":"2015"},{"key":"CIT0108","volume-title":"Naloxone, OAR 855-041-2330","year":"2015"},{"key":"CIT0109","volume-title":"Drug overdose response immunity, 35 P.S. \u00a7 780-113.7","year":"2014"},{"key":"CIT0110","unstructured":"Drug overdose medication, 35 P.S. \u00a7 780-113.8 (2014)."},{"key":"CIT0111","volume-title":"Rules and Regulations pertaining to opioid overdose prevention and reporting, 31 RI Adc D","volume":"2","year":"2015"},{"key":"CIT0112","volume-title":"Overdose prevention and education, R.I. Admin. Code 46-1-13:46.0","year":"2015"},{"key":"CIT0113","volume-title":"South Carolina Overdose Prevention Act, H.B. 3083","year":"2015"},{"key":"CIT0114","volume-title":"Opioid antagonist defined, SDCL \u00a7 34-20A-99","year":"2015"},{"key":"CIT0115","volume-title":"An act to provide for the possession and administration of opioid antagonists by first responders for the treatment of drug overdoses, S.B. 14","year":"2015"},{"key":"CIT0116","volume-title":"Opioid antagonists; usage; liability, T.C.A. \u00a7 63-1-152","year":"2014"},{"key":"CIT0117","volume-title":"An act relating to the prescription, administration, and possession of certain opioid antagonists for the treatment of suspected opioid overdoses, S.B. 1462","year":"2015"},{"key":"CIT0118","volume-title":"Emergency Administration of Opiate Antagonist Act, Utah Code Annotated, Title 26, Chapter 55","year":"2015"},{"key":"CIT0119","volume-title":"Opiate antagonist \u2013 immunity from liability, U.C.A. \u00a7 58-17b-507","year":"2015"},{"key":"CIT0120","volume-title":"Opiate antagonist \u2013 exclusion from unprofessional or unlawful conduct, U.C.A. \u00a7 58-31b-703","year":"2015"},{"key":"CIT0121","volume-title":"Naloxone hydrochloride; dispensing or furnishing","year":"2015"},{"key":"CIT0122","volume-title":"Prevention and treatment of opioid-related overdoses","year":"2015"},{"key":"CIT0123","volume-title":"Persons rendering emergency care, obstetrical services exempt from liability, VA Code Ann. \u00a7 8.01-225","year":"2015"},{"key":"CIT0124","volume-title":"Professional use by practitioners, VA Code Ann. \u00a7 54.1-3408","year":"2015"},{"key":"CIT0125","volume-title":"Medical assistance \u2013 drug-related overdose \u2013 naloxone \u2013 prosecution for possession, RCW \u00a7 69.50.315","year":"2015"},{"key":"CIT0126","volume-title":"Opioid overdose medication [Tentative classification and name line supplied by publisher], RCW \u00a7 69.41.0001","year":"2015"},{"key":"CIT0127","volume-title":"Prescription requirements \u2013 penalty, RCW \u00a7 69.41.040","year":"2015"},{"key":"CIT0128","volume-title":"Access to Opioid Antagonists Act, West Virginia Code, Chapter 16, Article 46","year":"2015"},{"key":"CIT0129","volume-title":"Opioid antagonists, W.S.A. \u00a7 256.40","year":"2014"},{"key":"CIT0130","volume-title":"Disciplinary proceedings and actions, W.S.A. \u00a7 441.07","year":"2014"},{"key":"CIT0131","volume-title":"Prescriptions for and delivery of opioid antagonists, W.S.A. \u00a7 441.18","year":"2014"},{"key":"CIT0132","volume-title":"Prescriptions for and delivery of opioid antagonists, W.S.A. \u00a7 448.037","year":"2014"},{"key":"CIT0133","volume-title":"Definitions, W.S.A. \u00a7 450.01","year":"2015"},{"key":"CIT0134","volume-title":"Prescription drugs and prescription devices, W.S.A. \u00a7 450.11","year":"2015"},{"key":"CIT0135","volume-title":"Civil liability exemption; emergency medical care, W.S.A. \u00a7 895.48","year":"2014"},{"key":"CIT0136","volume-title":"Office of the Attorney General State of Maryland, Opinion No"},{"key":"CIT0137","unstructured":"License required to practice medicine, MD Code, Health Occupations, \u00a7 14\u2013601 (2013)."},{"key":"CIT0138","volume-title":"Effect of violation, W.Y.1977 \u00a7 33-26-410","year":"2003"},{"key":"CIT0139","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-006-9120-z"},{"key":"CIT0140","volume-title":"The Network for Public Health Law. Legal Interventions to Reduce Overdose Mortality: Naloxone Access and Overdose Good Samaritan Laws"},{"key":"CIT0141","unstructured":"Manufacture or sale of adulterated or misbranded items prohibited, MD Code, Health \u2013 General, \u00a7 21\u2013256 (1988)."},{"key":"CIT0142","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-3959(01)00080-9"},{"key":"CIT0143","volume-title":"Naloxone Overdose Prevention Laws Map","author":"Public Health Law Research"},{"key":"CIT0144","volume-title":"By end of August, CVS will offer Narcan without prescription to counter opiate overdoses","author":"Borg L."},{"key":"CIT0145","volume-title":"Boston Medical Center teams up with Rhode Island Hospital, CVS Health to address use of pharmacy-based naloxone to combat opioid addiction and overdoses","author":"CVS Health"},{"key":"CIT0146","volume-title":"New Mexico pharmacists to prescribe anti-overdose drug","author":"Krasnow B.","year":"2014"},{"key":"CIT0147","unstructured":"License denial, suspension, or revocation, MD Code, Health Occupations, \u00a7 14\u2013404 (2015)."},{"key":"CIT0148","volume-title":"Unprofessional conduct \u2013 Definition, 59 Okl.St.Ann. \u00a7 509","year":"2009"},{"key":"CIT0149","volume-title":"Grounds for suspending, revoking or refusing to grant license, registration or certification; alternative medicine, O.R.S. \u00a7 677.190","year":"2010"},{"key":"CIT0150","volume-title":"Naloxone Access: Status of State Laws Map","author":"National Alliance for Model State Drug Laws"},{"key":"CIT0151","volume-title":"Office of National Drug Control Policy, Office of Public Affairs. Fact sheet: Preventing, treating, and surviving overdose","author":"Available from"},{"key":"CIT0152","volume-title":"National Drug Control Strategy. The White House website","author":"Executive Office of the President of the United States"},{"key":"CIT0153","first-page":"989","volume":"52","year":"2014","journal-title":"Expanding access to naloxone in the United States. Clin Toxicol"},{"key":"CIT0154","volume-title":"Naloxone Legislation Drafting Guide. Harm Reduction Coalition website","author":"Naloxone Overdose Prevention and Education (NOPE) Working Group"},{"key":"CIT0155","volume-title":"About. National Alliance for Model State Drug Laws website","author":"National Alliance for Model State Drug Laws"},{"key":"CIT0156","volume-title":"Naloxone Access Statutes","author":"National Alliance for Model State Drug Laws"},{"key":"CIT0157","unstructured":"Lexicomp Online\u00ae, Lexi-Drugs\u00ae, Hudson, Ohio: Lexi-Comp, Inc. August 18, 2015."},{"key":"CIT0158","volume-title":"Opiate Overdose Treatment: Naloxone Training Protocol","author":"Oregon Health Authority"}],"container-title":["The American Journal of Drug and Alcohol Abuse"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/00952990.2015.1109648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T10:59:39Z","timestamp":1600081179000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.3109\/00952990.2015.1109648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,25]]},"references-count":157,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,23]]},"published-print":{"date-parts":[[2016,3,3]]}},"alternative-id":["10.3109\/00952990.2015.1109648"],"URL":"https:\/\/doi.org\/10.3109\/00952990.2015.1109648","relation":{},"ISSN":["0095-2990","1097-9891"],"issn-type":[{"value":"0095-2990","type":"print"},{"value":"1097-9891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iada20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iada20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]}}